Dr. Jed Pollack, MD
Claim this profileLenox Hill Brain Tumor Center
Studies Glioblastoma
Studies Brain Cancer
3 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Jed Pollack, MD is currently running
Cetuximab + Reirradiation
for Brain Cancer
Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression of EFGR (Epidermal Growth Factor Receptor), which is associated with poor prognosis. Several methods of inhibiting this receptor have been tested, including monoclonal antibodies, vaccines, and tyrosine kinase inhibitors. The investigators hypothesize that in patients with recurring GBM, intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2 in conjunction with hypofractionated radiation, will be safe and efficacious and prevent tumor progression in patients with recurrent, residual GBM.
Recruiting3 awards Phase 21 criteria
Intra-arterial Cetuximab
for Newly Diagnosed Glioblastoma
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol). This trial will be a non-randomized open label Phase I/II clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.
Recruiting3 awards Phase 1 & 2
More about Jed Pollack, MD
Clinical Trial Related9 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jed Pollack, MD has experience with
- Cetuximab
- Cetuximab (Erbitux)
- Hypofractionated Re-irradiation
- Mannitol
Breakdown of trials Jed Pollack, MD has run
Glioblastoma
Brain Cancer
Brain Tumor
Brain Metastases
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jed Pollack, MD specialize in?
Jed Pollack, MD focuses on Glioblastoma and Brain Cancer. In particular, much of their work with Glioblastoma has involved EGFR positive patients, or patients who are undergoing treatment.
Is Jed Pollack, MD currently recruiting for clinical trials?
Yes, Jed Pollack, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Jed Pollack, MD has studied deeply?
Yes, Jed Pollack, MD has studied treatments such as Cetuximab, Cetuximab (Erbitux), Hypofractionated re-irradiation.
What is the best way to schedule an appointment with Jed Pollack, MD?
Apply for one of the trials that Jed Pollack, MD is conducting.
What is the office address of Jed Pollack, MD?
The office of Jed Pollack, MD is located at: Lenox Hill Brain Tumor Center, New York, New York 10075 United States. This is the address for their practice at the Lenox Hill Brain Tumor Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.